Company Overview - Mercury Systems (MRCY) is expected to report a year-over-year decline in earnings due to lower revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.21, reflecting an 8.7% decrease from the previous year [1][3] - Revenues are anticipated to be $241.71 million, down 2.8% from the same quarter last year [3] Earnings Expectations - The upcoming earnings report is scheduled for August 11, and the stock may rise if the actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Most Accurate Estimate for Mercury Systems is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.05%, suggesting a more optimistic outlook from analysts [11] - However, the company currently holds a Zacks Rank of 5, which complicates the prediction of an earnings beat [11] Historical Performance - In the last reported quarter, Mercury Systems met the expected EPS of $0.06, resulting in no surprise [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Comparison - Curtiss-Wright (CW), a peer in the Aerospace - Defense Equipment industry, is expected to report an EPS of $3.13 for the same quarter, indicating a year-over-year increase of 17.2% [17] - Revenues for Curtiss-Wright are projected to be $850.49 million, up 8.4% from the previous year, with a positive Earnings ESP of +0.67% and a Zacks Rank of 2, suggesting a likely earnings beat [18][19]

Company Overview - Taysha Gene Therapies, Inc. (TSHA) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly loss of $0.07 per share, representing a 22.2% improvement from the previous year [1][3] - Revenues are anticipated to reach $1.72 million, reflecting a 55% increase compared to the same quarter last year [3] Earnings Estimates and Trends - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections [4] - The Most Accurate Estimate for Taysha Gene Therapies is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -14.29%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Taysha Gene Therapies currently holds a Zacks Rank of 2, but the negative Earnings ESP complicates the prediction of an earnings beat [12] Historical Performance - In the last reported quarter, Taysha Gene Therapies was expected to post a loss of $0.08 per share and did so, resulting in no surprise [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - Amphastar Pharmaceuticals (AMPH), another player in the Zacks Medical - Generic Drugs industry, is expected to report earnings per share of $0.71 for the same quarter, indicating a year-over-year decline of 24.5% [18] - Revenues for Amphastar are projected to be $169.84 million, down 6.9% from the previous year, with an Earnings ESP of -11.97% [19][20]

Core Viewpoint - The market anticipates that Monday.com (MNDY) will report a year-over-year decline in earnings despite higher revenues in its upcoming earnings report for the quarter ended June 2025 [1][3]. Earnings Expectations - The consensus estimate for Monday.com's quarterly earnings is $0.84 per share, reflecting a year-over-year decrease of 10.6% [3]. - Expected revenues for the quarter are $293.15 million, which represents a 24.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4]. - A positive Earnings ESP of +3.30% suggests that analysts have recently become more optimistic about Monday.com's earnings prospects [12]. Earnings Surprise Potential - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [10]. - Monday.com currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Monday.com exceeded the expected earnings of $0.70 per share by delivering $1.10, resulting in a surprise of +57.14% [13]. - The company has successfully beaten consensus EPS estimates in the last four quarters [14]. Industry Context - StoneCo Ltd. (STNE), another player in the Zacks Internet - Software industry, is expected to report earnings of $0.36 per share for the same quarter, indicating a year-over-year increase of 20% [18]. - StoneCo's revenues are projected to be $653.09 million, up 6.2% from the previous year [18]. - The consensus EPS estimate for StoneCo has been revised up by 5.9% over the last 30 days, and it has an Earnings ESP of +12.68%, suggesting a strong likelihood of beating the consensus EPS estimate [19].

Core Insights - Bio-Techne Corporation (TECH) is scheduled to release its fourth-quarter fiscal 2025 results on August 6, before market opening [1] - The company reported adjusted earnings per share (EPS) of 56 cents in the last quarter, exceeding the Zacks Consensus Estimate by 9.8%, with an average surprise of 6.74% over the past four quarters [1][3] Q4 Estimates for TECH - The Zacks Consensus Estimate for Bio-Techne's revenues is $317.4 million, reflecting a 3.7% increase from the previous year [2] - The EPS estimate suggests a 2% year-over-year improvement to 50 cents [2] Estimate Revision Trend - Earnings estimates for the fourth quarter have remained stable at 50 cents over the past 60 days [3] Factors Impacting Performance - Management noted macro uncertainties, including tariffs and potential NIH budget cuts, which could temporarily slow growth momentum in Q4 [4] - The Protein Sciences division accounted for 72% of net sales in Q3, with potential modest impacts from the divestment of the fetal bovine serum business [5] Growth Drivers - Bio-Techne is expected to benefit from strong demand for research reagents, protein analysis tools, and cell therapy workflow solutions [6] - The FDA's shift away from animal testing may enhance growth for Bio-Techne's organoid solutions, providing ethical and cost-effective alternatives [7] - The protein analytical instrumentation business, particularly the Maurice platform, is anticipated to show strong momentum [8][9] Segment Performance - The Biologics segment's revenue estimate is $225 million, up 5.1% from the previous year, driven by instrument placements and consumables [9] - The Spatial Biology segment is expected to generate $93 million in revenue, a 2.2% increase year-over-year, despite facing NIH funding uncertainties [12] Earnings ESP and Zacks Rank - Bio-Techne has an Earnings ESP of 0.00%, indicating no expected earnings surprise [13] - The company currently holds a Zacks Rank of 4 (Sell) [13]

Core Viewpoint - EOG Resources, Inc. is expected to report second-quarter 2025 results on August 7, with earnings per share estimated at $2.20, reflecting a 30.4% decline year-over-year [1][8] Earnings Performance - In the last reported quarter, EOG's adjusted earnings were $2.87 per share, exceeding the Zacks Consensus Estimate of $2.74, driven by higher production volumes [1] - EOG has consistently surpassed the Zacks Consensus Estimate in the past four quarters, with an average surprise of 6.02% [1] Revenue Expectations - The Zacks Consensus Estimate for revenues in the upcoming quarter is $5.43 billion, indicating a 9.8% decrease from the previous year [2] Production and Operational Factors - EOG is anticipated to have stable performance in Q2 2025, supported by productive acreages in key oil shale plays like the Permian and Eagle Ford, along with numerous untapped high-quality drilling sites [3] - However, the company is facing margin pressure due to lower commodity prices, which have negatively impacted upstream profitability despite steady production levels [4] Financial Strategy - EOG has reduced its 2025 capital expenditure budget by $200 million, indicating a cautious investment approach amid uncertain pricing and demand trends [4] - The company is also dealing with higher financing costs related to its $5.6 billion acquisition of Encino Acquisition Partners, which added approximately $3.5 billion in new debt [4] Earnings Outlook - Current analysis suggests that EOG may not achieve an earnings beat this quarter, with an Earnings ESP of -0.89% and a Zacks Rank of 3 (Hold) [6]

Core Insights - MetLife, Inc. is scheduled to report its second-quarter 2025 results on August 6, with earnings estimated at $2.19 per share and revenues at $18.4 billion [1] Earnings Estimates - The earnings estimate for the second quarter has improved over the past 30 days, but it reflects a year-over-year decline of 4%, while revenues are expected to decline by 1.5% year-over-year [2] - For the current year, MetLife's revenue estimate stands at $74.8 billion, indicating a 2.4% year-over-year increase, and the EPS estimate is $8.96, suggesting a 10.5% increase year-over-year [3] Earnings Prediction Model - The current model does not predict an earnings beat for MetLife, as it has an Earnings ESP of +0.67% and a Zacks Rank of 4 (Sell) [4] Factors Influencing Q2 Results - Rising adjusted group benefits revenues are expected to positively impact MetLife's second-quarter results, with significant contributions from operations in Asia and Latin America [5] - The Zacks Consensus Estimate for total adjusted group benefits suggests a 2.9% increase year-over-year, driven by improved profits from Asia and Latin America [6] - However, rising costs and a projected 1.4% decline in investment income may offset profit growth [6][8] Regional Performance - The Asia segment is likely to benefit from improved underwriting and variable investment income, while the Latin America business is expected to see growth from higher volumes, with adjusted earnings from Latin America projected to grow by 0.4% year-over-year [7]

Core Viewpoint - Astronics Corporation (ATRO) is expected to report second-quarter 2025 results on August 6, with projected revenues of $207.1 million, reflecting a 4.5% year-over-year growth, and earnings estimated at 33 cents per share, indicating a significant 725% increase from the previous year's 4 cents [1][4]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $207.1 million, which represents a 4.5% increase from the same quarter last year [1][4]. - The earnings consensus is set at 33 cents per share, suggesting a substantial improvement of 725% from the prior year's figure of 4 cents [1][4]. Segment Performance - The Aerospace segment is anticipated to drive sales growth, with expected sales of $190.2 million, up 7.5% year-over-year, due to increased demand for cabin power, in-flight entertainment, and military aircraft products [5][6]. - The Test Systems unit is projected to see a decline in sales, estimated at $16.9 million, down 20% from the previous year, attributed to delays and cost challenges [7]. Historical Performance - Astronics has a strong earnings surprise history, beating the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 55.64% [2][3]. Stock Performance and Valuation - ATRO's stock has increased by 84% over the past six months, outperforming the Zacks Aerospace-Defense Equipment industry's gain of 20.5% and the broader sector's rise of 19% [10]. - The forward 12-month price-to-earnings (P/E) ratio for ATRO is 20.21X, which is significantly lower than the peer group's average of 49.78X, indicating a more attractive valuation relative to expected earnings growth [11][14]. Industry Context - The aerospace and defense industry presents substantial growth opportunities, driven by expanding commercial air traffic and a solid presence in the defense sector, which provides a diversified cushion against crises [16]. - However, challenges such as supply chain pressures, raw material costs, and labor availability persist, which could impact performance [15][17].

Core Viewpoint - Eli Lilly and Company (LLY) is set to report its second-quarter earnings on August 7, with sales and earnings estimates at $14.75 billion and $5.61 per share respectively. Earnings estimates for 2025 have increased slightly from $21.92 to $22.05 per share over the past month [1][6]. Group 1: Earnings Performance - LLY has had a mixed earnings surprise history, exceeding expectations in two of the last four quarters and missing in the other two, with an average surprise of 6.69% [3]. - The last reported quarter saw a negative earnings surprise of 5.11% [3][4]. Group 2: Factors Influencing Upcoming Results - The anticipated growth in LLY's second-quarter results is expected to be driven by strong demand for its GLP-1 drugs, particularly diabetes drug Mounjaro and weight loss medicine Zepbound [6][7]. - Sales of Mounjaro and Zepbound are projected at $4.58 billion and $3.1 billion respectively, with LLY's own estimates slightly lower at $4.46 billion and $3.09 billion [9]. - Increased demand for other key drugs like Emgality, Jardiance, Olumiant, Taltz, and Verzenio is also expected to support top-line growth, despite pricing pressures and competitive dynamics [10][12]. Group 3: Competitive Landscape and Market Dynamics - LLY faces significant competition in the GLP-1 market, particularly from Novo Nordisk's semaglutide products, which could impact Mounjaro and Zepbound's market share [25][26]. - The company is diversifying its pipeline beyond GLP-1 drugs, with recent acquisitions aimed at expanding into cardiovascular, oncology, and neuroscience areas [23][24]. Group 4: Stock Performance and Valuation - LLY's stock has decreased by 0.9% year-to-date, compared to a 3.3% decline in the industry [15]. - Despite a premium valuation, the company is recommended for retention due to its robust growth prospects and position as a leading drugmaker [27].

Core Viewpoint - Petrobras (PBR) is expected to report second-quarter earnings of 71 cents per share on revenues of $20.8 billion, reflecting a significant year-over-year growth in earnings but a decline in revenues compared to the previous year [1][3]. Group 1: Previous Quarter Performance - In the first quarter, Petrobras reported adjusted earnings of 62 cents per ADS, missing the Zacks Consensus Estimate of 92 cents, with revenues of $21 billion also falling short of the $21.6 billion estimate [2]. - The company has beaten the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 3.3% [3]. Group 2: Production and Operational Highlights - Petrobras is projected to have a strong second quarter, with total oil, gas, and natural gas liquids production increasing by 5% quarter-over-quarter to 2.91 million barrels of oil equivalent per day (MMboed) [4]. - The company brought 14 new wells online, contributing to production milestones, including a record 4.19 MMboed of operated production and 2.39 MMboed of pre-salt output [5]. - Refining performance improved, with overall oil product production rising by 1.4% to 1,730 mbpd, and diesel output increasing by 2.4% to 680 mbpd [6]. Group 3: Challenges and Outlook - Despite the positive production growth, Petrobras faced higher losses due to stoppages and maintenance, along with a natural decline in production [7]. - The Zacks model does not predict an earnings beat for PBR this time, as the Earnings ESP is 0.00% [10].

Core Insights - DENTSPLY SIRONA Inc. is set to release its second-quarter 2025 results on August 7, with expectations of revenue at $851.6 million and earnings at 29 cents per share [2][3] Group 1: Q2 Performance Expectations - The company has shown an average earnings surprise of 2.73% over the past four quarters, indicating a potential for positive performance [2] - The Imaging segment is expected to benefit from the relaunch of Orthophos SL and Primescan 2, which may have driven growth, particularly in Europe and APAC [4] - Orthodontics, particularly SureSmile, is anticipated to show stable global growth, although U.S. performance may be hindered by softer discretionary spending [5] Group 2: Challenges and Headwinds - The suspension of Byte aligner sales is projected to negatively impact organic sales by approximately two percentage points in 2025, affecting second-quarter results as well [6] - Essential Dental Solutions may have experienced stable patient traffic, but overall segment growth is likely to be limited by softness in elective procedures and weak U.S. implant sales [7] - Connected Technology Solutions, including CAD/CAM, continues to face macroeconomic pressures, with subdued retail demand in the U.S. despite growth in Germany [8] Group 3: Operational Insights - DENTSPLY SIRONA's Phase II transformation activities are on track to deliver full run-rate savings by the end of 2025, with expectations of gradual stabilization in gross margins throughout the year [9] - Cost initiatives and SKU rationalization may contribute to improved gross margins, aiding quarter-over-quarter growth in Q2 [11] Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for DENTSPLY SIRONA, with an Earnings ESP of -0.99% and a Zacks Rank of 2 [12][13]